#mcspc نتائج البحث
📢Darolutamide FDA-approved for de novo mCSPC Prostate Cancer on 6/3/25! ✅10-yr timeline: 2015 (Docetaxel HR 0.73) → 2025 (Darolutamide OS HR 0.81). 📉rPFS HR 0.54. Trial populations matter! 📰In-Depth Article: oncologytube.com/darolutamide-f… #mCSPC #FDAApproval #OncoTwitter…
Improvements in OS regardless of volume status in #mCSPC #ProstateCancer treated w/ #darolutamide and #docteaxel vs. chemo but worth asking if there is sufficient statistical power here to escalate therapy in patients with low volume disease where chemo is now out of favor. #GU23
@cityofhope @TDorffOnc excellent discussant session w/an eye towards future personalized and molecular-guided #mCSPC systemic therapy landscape and de-escalation of ADT + ARPI if PSA nadir <0.2 after 1 yr ARPI @ASCO #GU25 @OncoAlert
ADT alone is not enough, upfront combo is needed for all patients with #mCSPC. Data shown in this #AUA2023 session were US + Japanese data (pics attached). European data seem slightly better (also for urologists) but there is clear room for improvement for evidence-based medicine
Kicking off the #ASCO23 #prostate oral session PEACE-1 results by @AlbertoBossial RT in low volume de novo #mCSPC improves rPFS and CRPS-free survival and prevents serious GU events. Is is time for a "quadruplet" in high burden mCSPC?
Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not all visceral mets are equal in #ProstateCancer. New multicenter mCSPC study shows patients with lung-only metastases have better outcomes than those with…
PhII rand Metacure trial of oligo #mCSPC SBRT to all mets + ADT + apa +/- abi ➡️ PSA0 w/T recovery (primary endpt) met with 42% with short ADT + apa and 50% w/short course ADT + apa and combined group with abi #ASCO25 @OncoAlert
@AlanBryce9 PhIII TRITON3 #PARPi rucaparib superior rPFS vs IC (doce or 2nd-gen ARSI) in chemo-naive #mCRPC (1 prior ARSI & prior chemo allowed in #mCSPC) in #BRCA (64% BRCA2) but not #ATM mt , interim OS 24 vs 20 mos (54% mature in BRCA), 75% crossover @OncoAlert @ASCO #GU23
@JosephBBlack work @AmerUrological #AUA2023 assessing prescription patterns for management of #mCSPC with lots of interest from the audience.
Maha Hussain summarizing doublet/triplet treatment for #mCSPC based on #TITAN #ENZAMET #ARASENS #PEACE1. Which patients benefit most from triplet T suppression+NHT+docetaxel? Based on #ENZAMET mainly synch HV. Interesting to see responses to questions asked #AUA2023
Just in👉bit.ly/3AMRBec Real world claims analysis of 10 AEs in #mCSPC. AE rates⬆️over time across Rx groups. Most AE rates with ADT+ARPIs were comparable to ADT+NSAA & ADT alone. ADT+docetaxel had⬆️rates of 7 AEs. Sexual function AE didn't differ between Rx. @OncoAlert
Clear from #EMBARK @NEJM #BCR not🚫just #mCSPC #ProstateCancer when you do #PSMA PET🩻 ✴️A 5 yr MFS of 70-90% in EMBARK very different than 4-5 yr median OS in mCSPC Data from PRE-Abi/Enza era shows median OS for BCR was 9+ yrs 🚨BCR=more indolent biology should be tx as such
At #GU24, @WallisCJD highlighted his population-based research on treatment intensification shortcomings in de novo #mCSPC. Learn more: buff.ly/3SHPW08
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Role of prostate irradiation in de novo low-volume #mCSPC? New SOC “Quadruplet Txt”? ➡️Updated results of #PEACE1: Ph3 trial @AlbertoBossial @GustaveRoussy Intensified txt improved: ✅rPFS ✅CRPC free-survival ❌No impact of RT on OS Minimal added toxicity #ASCO23 @OncoAlert
Dr. Elias Chandran @EliasChandran presents unique data re: #immune changes after #docteaxel in #mCSPC #ProstateCancer @asco #GU23 today! Poster #F8 This data may highlight a better path forward for #Immunotherapy in Prostate Cancer. #NKcells meetings.asco.org/abstracts-pres…
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
The AMPLITUDE results with niraparib/AAP could redefine treatment for HRR-altered mCSPC - impressive rPFS gains with manageable safety. #pcsm #mCSPC
WATCH: Biren Saraiya, MD, provides background on the phase 3 AMPLITUDE study evaluating niraparib + abiraterone acetate in metastatic castration-sensitive prostate cancer. #pcsm #mCSPC hubs.li/Q03v36DF0
#ASCO25 News: FDA approves darolutamide for metastatic castration-sensitive prostate cancer based on ARANOTE trial. Median rPFS not reached—HR 0.54 (P <.0001). bit.ly/3HEoo8J #ProstateCancer #mCSPC @TGAgovau @GovCanHealth @Swissmedic_ @MHRAgovuk
#ASCO25 #mCSPC News: Study #AMPLITUDE: Niraparib + AAP cut radiographic progression risk by 48% in BRCA-mutated metastatic castration-sensitive prostate cancer. A potential new standard? bit.ly/3ZRFB4R #ProstateCancer @uclcancer @quimmateo
oncologynewscentral.com
Is Niraparib Combo the New Standard for Certain Prostate Cancers
Niraparib with abiraterone acetate plus prednisone reduces the risk for radiographic progression for some patients with metastatic prostate cancer, phase 3 data show.
Could earlier genomic testing be the key to better prostate cancer treatment? Gerhardt Attard presents the updates from #ASCO25 you need to know, including a new approach in #mCSPC that can significantly reduce disease progression #MedX #Oncology ow.ly/4Xmb50Wa5eX
In BCR: Apalutamide/Darolutamide. Fit & high-risk: PEACE-1 → Darolutamide triplet. Visceral mets: Abiraterone for rapid cytoreduction. Elderly/frail: Darolutamide for CNS safety. So… where does Enzalutamide truly belong? #ProstateCancer #mCSPC #Oncology
Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not all visceral mets are equal in #ProstateCancer. New multicenter mCSPC study shows patients with lung-only metastases have better outcomes than those with…
📢Darolutamide FDA-approved for de novo mCSPC Prostate Cancer on 6/3/25! ✅10-yr timeline: 2015 (Docetaxel HR 0.73) → 2025 (Darolutamide OS HR 0.81). 📉rPFS HR 0.54. Trial populations matter! 📰In-Depth Article: oncologytube.com/darolutamide-f… #mCSPC #FDAApproval #OncoTwitter…
#ASCO25 #mCSPC News: Study #AMPLITUDE: Niraparib + AAP cut radiographic progression risk by 48% in BRCA-mutated metastatic castration-sensitive prostate cancer. A potential new standard? bit.ly/3ZRFB4R #ProstateCancer @uclcancer @quimmateo
oncologynewscentral.com
Is Niraparib Combo the New Standard for Certain Prostate Cancers
Niraparib with abiraterone acetate plus prednisone reduces the risk for radiographic progression for some patients with metastatic prostate cancer, phase 3 data show.
Niraparib Combo Lowers Progression Risk in HRR-Altered #mCSPC | #ASCO25 hubs.li/Q03qxMpW0
#ASCO25 News: FDA approves darolutamide for metastatic castration-sensitive prostate cancer based on ARANOTE trial. Median rPFS not reached—HR 0.54 (P <.0001). bit.ly/3HEoo8J #ProstateCancer #mCSPC @TGAgovau @GovCanHealth @Swissmedic_ @MHRAgovuk
🚨 @FDA approves #Darolutamide Darolutamide (#Nubeqa) is now approved for metastatic castration-sensitive prostate cancer #mCSPC as monotherapy! 🧬 Approval backed by data from the #ARANOTE trial showing significant rPFS benefit. #ProstateCancer #GUonc #FDA #ReadNow details on…
🚨BREAKING: The #FDA has approved darolutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. #mCSPC #pcsm urologytimes.com/view/fda-appro…
BREAKING: The #FDA has approved darolutamide (Nubeqa) for the treatment of metastatic castration-sensitive prostate cancer. #pcsm #mCSPC hubs.li/Q03qwnWy0
Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not all visceral mets are equal in #ProstateCancer. New multicenter mCSPC study shows patients with lung-only metastases have better outcomes than those with…
@cityofhope @TDorffOnc excellent discussant session w/an eye towards future personalized and molecular-guided #mCSPC systemic therapy landscape and de-escalation of ADT + ARPI if PSA nadir <0.2 after 1 yr ARPI @ASCO #GU25 @OncoAlert
ADT alone is not enough, upfront combo is needed for all patients with #mCSPC. Data shown in this #AUA2023 session were US + Japanese data (pics attached). European data seem slightly better (also for urologists) but there is clear room for improvement for evidence-based medicine
@AlanBryce9 PhIII TRITON3 #PARPi rucaparib superior rPFS vs IC (doce or 2nd-gen ARSI) in chemo-naive #mCRPC (1 prior ARSI & prior chemo allowed in #mCSPC) in #BRCA (64% BRCA2) but not #ATM mt , interim OS 24 vs 20 mos (54% mature in BRCA), 75% crossover @OncoAlert @ASCO #GU23
@JosephBBlack work @AmerUrological #AUA2023 assessing prescription patterns for management of #mCSPC with lots of interest from the audience.
Dr. Elias Chandran @EliasChandran presents unique data re: #immune changes after #docteaxel in #mCSPC #ProstateCancer @asco #GU23 today! Poster #F8 This data may highlight a better path forward for #Immunotherapy in Prostate Cancer. #NKcells meetings.asco.org/abstracts-pres…
Kicking off the #ASCO23 #prostate oral session PEACE-1 results by @AlbertoBossial RT in low volume de novo #mCSPC improves rPFS and CRPS-free survival and prevents serious GU events. Is is time for a "quadruplet" in high burden mCSPC?
Barriers to and facilitators of 1st-line treatment intensification in #mCSPC by practice setting and intensification frequency: A sub-analysis of #IMPLEMENT Why is 1L treatment intensification underused in #mCSPC? A sub-analysis of IMPLEMENT highlights key barriers (knowledge…
Role of prostate irradiation in de novo low-volume #mCSPC? New SOC “Quadruplet Txt”? ➡️Updated results of #PEACE1: Ph3 trial @AlbertoBossial @GustaveRoussy Intensified txt improved: ✅rPFS ✅CRPC free-survival ❌No impact of RT on OS Minimal added toxicity #ASCO23 @OncoAlert
Clear from #EMBARK @NEJM #BCR not🚫just #mCSPC #ProstateCancer when you do #PSMA PET🩻 ✴️A 5 yr MFS of 70-90% in EMBARK very different than 4-5 yr median OS in mCSPC Data from PRE-Abi/Enza era shows median OS for BCR was 9+ yrs 🚨BCR=more indolent biology should be tx as such
Evaluation of the Impact on OS curves of patients with #mCSPC staged with PSMA-PET and classified according to current prognostic criteria by volume and risk. PSMA-PET redefines prognostic classification in mCSPC! 🔹 67% increase in metastatic detection vs. conventional imaging…
PhII rand Metacure trial of oligo #mCSPC SBRT to all mets + ADT + apa +/- abi ➡️ PSA0 w/T recovery (primary endpt) met with 42% with short ADT + apa and 50% w/short course ADT + apa and combined group with abi #ASCO25 @OncoAlert
Maha Hussain summarizing doublet/triplet treatment for #mCSPC based on #TITAN #ENZAMET #ARASENS #PEACE1. Which patients benefit most from triplet T suppression+NHT+docetaxel? Based on #ENZAMET mainly synch HV. Interesting to see responses to questions asked #AUA2023
Improvements in OS regardless of volume status in #mCSPC #ProstateCancer treated w/ #darolutamide and #docteaxel vs. chemo but worth asking if there is sufficient statistical power here to escalate therapy in patients with low volume disease where chemo is now out of favor. #GU23
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive #mCSPC #ProstateCancer Interesting data from @neerajaiims & colleagues now published @JUrology auajournals.org/doi/epdf/10.10…
🚨 @FDA approves #Darolutamide Darolutamide (#Nubeqa) is now approved for metastatic castration-sensitive prostate cancer #mCSPC as monotherapy! 🧬 Approval backed by data from the #ARANOTE trial showing significant rPFS benefit. #ProstateCancer #GUonc #FDA #ReadNow details on…
PET imaging for #mCSPC for patients with PSA response after systemic therapy: A multicentric ambispective analysis. PSMA PET shows 81% complete response in mCSPC patients with PSA <0.2 ng/mL after systemic therapy! While not routine, PET could help guide treatment…
@NCCN 2024 #ProstateCancer Guidelines Update: #Relugolix gains prominence in treating #mCSPC. @RKSayyid @USC & @zklaassen_md @gacancercenter explore significant updates in this space. #WatchNow on UroToday > bit.ly/47uMLPc
Something went wrong.
Something went wrong.
United States Trends
- 1. Chiefs 109K posts
- 2. Branch 33.7K posts
- 3. Mahomes 33.3K posts
- 4. Red Cross 39.2K posts
- 5. #TNABoundForGlory 55.4K posts
- 6. Binance DEX 5,171 posts
- 7. #LaGranjaVIP 71.2K posts
- 8. #LoveCabin 1,194 posts
- 9. Rod Wave 1,336 posts
- 10. Bryce Miller 4,462 posts
- 11. Dan Campbell 3,876 posts
- 12. Goff 13.7K posts
- 13. LaPorta 10.8K posts
- 14. Kelce 16.7K posts
- 15. #OnePride 6,397 posts
- 16. Mariners 50K posts
- 17. #DETvsKC 4,989 posts
- 18. Butker 8,508 posts
- 19. Eitan Mor 8,128 posts
- 20. Omri Miran 8,446 posts